-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $8

Benzinga·05/06/2025 09:21:11
Listen to the news
Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $11 to $8.